A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial Tumors
A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial Tumors
Recruiting · NCT06248515 · Registry updated 2026-09-11Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial Tumors | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Thoracic Neoplasms, Thymus Neoplasms, lymphatic system disorder, mixed neoplasm, neoplasm, thymoma | Recruiting | Phase 2 | 2026-09-11 | NCT06248515 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Georgetown University | 73 |
| Gilead Sciences | 180 |
4 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| John Theurer Cancer Center at Hackensack University Medical Center | Hackensack | United States | 37 |
| Lombardi Comprehensive Cancer Center, Georgetown University | Washington D.C. | United States | 7 |
| Stanford Cancer Institute | Palo Alto | United States | 21 |
| University of Chicago Medical Center | Chicago | United States | 152 |